Summit Therapeutics SMMT Cash Flow Statement (2017-2026)

NASDAQ SMMT
$17.60 +0.48 (+2.77%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Summit Therapeutics Quarterly Cash Flow Statement

Periods 39 quarters
Latest Jun 2026

Summit Therapeutics reported cash from operations of -$141.12M and free cash flow of -$141.34M for the quarter ended Jun 2026, down 111.4% year over year. This cash flow statement covers 39 quarters of results from Apr 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Mar2019 Jul2019 Sep2019 Oct2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-19.60M-27.10M-22.16M-12.69M-16.94M-20.30M-536.19M-15.79M-20.49M-36.21M-45.51M-62.72M-60.83M-65.62M
Share-based CompensationStock Comp.
5.62M4.00M2.50M2.76M2.66M2.77M4.25M0.70M8.75M9.51M11.09M19.37M11.02M11.10M478.78M130.76M111.78M72.79M68.71M
Deferred Taxes
Gains from Investment SecuritiesGains Investment
Asset Writedowns and ImpairmentWritedown
8.47M0.47M
Cash from OperationsCash from Ops.
-23.57M-9.18M-19.00M-19.22M-8.55M5.19M-13.13M-29.27M-14.90M-19.46M-30.13M-33.00M-30.30M-48.67M-61.17M-66.74M-93.08M-101.94M-122.29M-141.12M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.29M0.34M0.30M0.26M0.40M-0.96M2.90M-1.19M0.21M0.40M1.60M2.92M-2.35M2.97M1.02M3.02M4.22M2.97M
Change in Working Capital
Change in ReceivablesChange Receivables
1.37M-0.93M-0.46M-0.70M-1.23M1.41M-0.35M-0.01M-0.00M
Change in Account PayablesChange Payables
-1.02M-1.36M2.76M-3.48M-1.04M-2.37M0.31M0.30M2.33M-0.67M3.70M-3.04M-0.18M1.53M0.36M17.93M-0.84M-2.15M6.80M-3.91M
Change in Accured ExpensesChange Accured Exp.
-0.42M1.76M-3.52M0.44M7.90M-0.04M-3.24M-4.29M-0.20M5.35M-2.23M5.93M5.89M2.28M-7.59M14.04M0.94M5.53M12.22M20.74M
Other Working Capital ChangesOther WC Changes
0.22M0.52M-2.66M-1.47M-3.42M0.28M
Investing Activities
Capital ExpendituresCapex
-0.00M0.12M0.36M0.29M-0.02M-0.01M0.05M0.02M0.05M0.00M-2.45M0.00M-0.01M2.60M1.42M2.25M0.86M-3.87M1.03M0.22M
Change in Acquisitions & DivestmentsChange Acquisitions
38.17M109.42M60.57M112.86M70.00M74.00M232.98M160.53M150.81M177.29M448.80M
Cash from Investing ActivitiesCash from Investing
0.00M-0.12M-0.36M-0.29M0.02M0.01M-645.06M0.21M-3.49M60.57M19.87M-200.08M-108.61M83.48M160.11M150.81M-0.07M-485.16M-0.24M222.90M
Financing Activities
Other financing activitiesOther financing
0.73M1.22M0.19M0.11M0.10M0.65M0.23M4.12M0.48M199.51M234.96M-0.10M5.66M1.66M492.72M3.80M3.67M
Cash from Financing ActivitiesCash from Financing
0.68M1.26M25.19M75.00M520.06M80.11M-0.08M0.23M6.25M0.48M200.21M204.14M-23.61M7.68M2.22M33.81M573.82M3.80M231.08M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
100.00M104.69M43.04M-0.00M31.76M468.27M
Additional items
Exchange Rate EffectFX Effect
-0.25M-0.42M-0.17M-0.60M-1.83M1.38M0.44M0.29M-0.17M0.27M-0.04M0.01M0.11M-0.11M0.04M0.06M0.02M-0.02M-0.02M0.00M
Change in Cash
-23.14M-8.46M5.66M-20.11M64.64M526.64M-577.64M-28.85M-18.32M47.63M-9.81M-32.86M65.34M11.09M106.66M86.35M-59.32M-13.29M-118.75M312.85M
Free Cash FlowFCF
-23.56M-9.30M-19.36M-19.51M-8.54M5.20M-13.18M-29.29M-14.95M-19.46M-27.69M-33.01M-30.28M-51.27M-62.59M-69.00M-93.94M-98.07M-123.32M-141.34M
Net Cash FlowNCF
-22.89M-8.04M5.83M-19.51M66.46M525.26M-578.08M-29.15M-18.15M47.36M-9.78M-32.87M65.23M11.20M106.62M86.29M-59.34M-13.27M-118.73M312.85M